[Results of the treatment of acute leukemia in adolescents].
In the course of 120 months we have prospectively treated 45 patients with acute leukemia aged 11 to 21 years: 33 with acute lymphoblastic leukemia (ALL) and 12 with acute myelogenous leukemia (AML). Patients with ALL were treated with St. Jude's protocol XI: there were five early deaths and complete remission (CR) was achieved in 76% (89% of those completing one month of treatment); median survival (SV) was 29 months and the 120-month SV was 35%. AML patients with promyelocytic leukemia were induced to remission using all-trans-retinoic acid, whereas those with other types of AML were given the classic 7 + 3 scheme: the CR rate was 85%, median survival has not been reached and the 33 month survival was 72%. Four patients with AML were given peripheral blood stem cell autografts as part of the post-remission therapy. Our data in ALL and AML appeared to be intermediate to those in children and adults.
Ruiz-Argüelles
G J
GJ
Centro de Hematología y Medicina Interna de Puebla, México, USA.
Apreza-Molina
M G
MG
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality; D007951:Leukemia, Myeloid / Q000401:mortality / Q000628:therapy; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy; D011446:Prospective Studies; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
D003561:Cytarabine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D003630:Daunorubicin